This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism.

We are studying an investigational drug called sodium dichloroacetate (DCA).

The purpose of this study is to find out how well surveys can measure disease activity in kids with lower back arthritis. The study will last for either 3 or 6 months and take 2 or 3 visits.

The main objective of this study is to see if repeat subcutaneous doses of dupilumab, the study medicine, helps to reduce eosinophilic inflammation in the stomach of participants with eosinophilic gastritis/ eosinophilic gastroenteritis compared to a placebo.

This study aims to design and optimize the Hypothyroidism Treatment Satisfaction Questionnaire (ThyTSQ) for measuring treatment satisfaction. 

The Dova study is for children below 18 years with primary Immune Thrombocytopenia (ITP) who have had an insufficient response to previous treatment.

We are asking teens with autism between the ages of 16-21 who have expressed interest in learning how to drive or have received their learner's permit in the past 3 months, and their parent/primary caregiver to participate in an interview study.

Our Driving after Concussion study needs the help of both healthy and recently concussed teen partners in our research to understand how concussion affects driving behaviors in teens.

Our team at the Congenital Hyperinsulinism Center at CHOP is working on a research study to determine whether an experimental gene therapy product, DTX401, is safe and effective in people with glycogen storage disease type Ia (GSDIa)

 A gene in stem cells will then be edited to help the stem cells make more fetal hemoglobin. Higher levels of fetal hemoglobin can improve red blood cell sickling.